Financial results: Bod Science; Zelira Therapeutics; Emyria; Epsilon Healthcare; Elixinol; MGC Pharma by Steve Jones August 1, 2023April 30, 2024 Bod Science is plotting a capital raise and investigating new revenue streams as it reassured the […]
Emyria shares take a hit as company raises another A$2.5 million by Steve Jones May 1, 2023April 30, 2024
Emyria eyes US market with launch of high-dose CBD capsule by Steve Jones April 24, 2023April 30, 2024
Company news: Health House; Little Green Pharma; Incannex; Emyria by Steve Jones and Martin Lane April 19, 2023April 30, 2024
Emyria strikes commercial deal with Aspen for over-the-counter product by Steve Jones April 4, 2023April 30, 2024
Company news: Neurotech; Emyria; InhaleRx by Martin Lane and Steve Jones March 23, 2023April 30, 2024
Financial results: Elixinol; Emyria; Epsilon; Avecho; Creso Pharma; AusCann; MGC Pharma; Botanix; Zelira by Martin Lane and Steve Jones March 1, 2023April 30, 2024
Company news: Delta 9 Cannabis; Little Green Pharma; Zelira Therapeutics; Emyria by Martin Lane and Steve Jones February 16, 2023April 30, 2024
Emyria and LGP shares soar after TGA approves limited access to MDMA and psilocybin by Steve Jones February 6, 2023April 29, 2024
Company news: Althea; Cann Group; Emyria; Neurotech; Bod Science; Elixinol; Creso Pharma; MGC Pharma by Steve Jones and Martin Lane January 31, 2023February 2, 2023